Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01076751 · ClinicalTrials.gov registry record
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 82
- Enrollment target
NCT01076751: Clinical Trial study, sponsored by Sanofi.
NCT01076751 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01076751 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 82 participants
- Enrollment target
Study Summary
Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others * Describe economic and patient-reported outcomes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-10 |
Why NCT01076751 stopped before completion
NCT01076751 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01076751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01076751 about?
NCT01076751 is a clinical study titled "Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients". Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to o...
What is the current status of trial NCT01076751?
This trial is currently terminated. The enrollment target is 82 participants. The study started on 2010-02. Estimated completion is 2010-10.
Who is sponsoring clinical trial NCT01076751?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia